Zubotamig is a chimeric humanized Ig(G1-κ_G1-λ2) monoclonal antibody that dually targets CD3 and VTCN1. This bispecific antibody is utilized in research for investigating T-cell engagement and immune checkpoint modulation in both in vitro cellular assays and in vivo oncology models.